Fulcrum Global Partners

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined rare diseases. The company utilizes its proprietary FulcrumSeek platform to identify drug targets that can modulate gene expression to treat the root cause of diseases. Its lead candidate, losmapimod, is currently in Phase 3 clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also developed pociredir (FTX-6058) for sickle cell disease, although development was recently deprioritized to focus on the FSHD program and a strategic collaboration with Sanofi. The company is headquartered in Cambridge, Massachusetts, and is publicly traded on the NASDAQ exchange.